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Medications such as ß-blockers are currently the primary treatment for patients with hereditary
arrhythmia syndromes such as long QT syndrome (LQTS) and catecholaminergic polymorphic ventricular
tachycardia (CPVT). However, these drugs are ineffective in some patients, and the other treatment
option, that is implantable cardioverter deﬁbrillator (ICD) implantation, is associated with signiﬁcant
complications in young and active patients. Left cardiac sympathetic denervation (LCSD) may reduce the
wide gap between life-long ß-blocker medication and ICD implantation. Although LCSD is highly
effective in prevention of cardiac events in patients with LQTS and CPVT, it is rarely used. The recently
introduced procedure video-assisted thoracoscopic LCSD is associated with short hospital stays and low
morbidity. Thus, LCSD is an important therapeutic option for patients with LQTS and CPVT.
& 2015 Japanese Heart Rhythm Society. Published by Elsevier B.V. This is an open access article under the
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There are several options for the treatment of hereditary ven-
tricular arrhythmias such as long QT syndrome (LQTS) and cate-
cholaminergic polymorphic ventricular tachycardia (CPVT).
Administration of ß-blocker medication remains a ﬁrst-line
treatment; nevertheless, certain patients may be refractory or
intolerant to these drugs [1–4]. Implantable cardioverter deﬁ-
brillators (ICD) are often implanted in high-risk patients to prevent
sudden death [1–4]. However, ICD implantation in young and
active patients necessitates life-long and routine deviceblished by Elsevier B.V. This is anreplacement and is furthermore associated with device malfunc-
tion (including inappropriate shocks), infection, and psychological
problems [2,4–6]. Although ICD shocks are generally effective for
ventricular ﬁbrillation; shocks for polymorphic ventricular tachy-
cardia (VT), bidirectional VT, and electrical storm may not be
effective in terminating these tachyarrhythmias; especially in
CPVT patients [2,4–8]. Therefore, the clinical gap between ß-
blocker medication and ICD implantation is wide and decisions
regarding the correct course of treatment are consequently
challenging.
Traditionally, the major clinical indications for left cardiac
sympathetic denervation (LCSD) are ß-blocker intolerance or
refractoriness, high risk of sudden death with ß-blocker treatment
(despite the patient being asymptomatic), frequent ICD shocks, oropen access article under the CC BY-NC-ND license
Fig. 1. Left cardiac sympathetic denervation performed using video-assisted thor-
acoscopic surgery.
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[2,4,6,8–14]. LCSD is especially effective in patients with poor ß-
blocker compliance as it has long-lasting effects [10,11]. LCSD in
patients with frequent ICD shocks signiﬁcantly reduces the num-
ber of shocks, thus improving quality of life [6,10,11]. Recently,
LCSD via a video-assisted thoracoscopic surgery (VATS) approach
has been used in patients with LQTS and CPVT, allowing for early
ambulation and short hospital stays with minimal perioperative
complications [6,13–17]. Despite these advantages, LCSD is rarely
used as a supplementary therapy to ß-blocker administration and
ICD implantation [1–4].
LCSD prevents norepinephrine release in the heart and raises
the threshold for ventricular ﬁbrillation without impairing myo-
cardial contractility or reducing heart rate [18–20]. Large, multi-
center studies have reported consistent efﬁcacy for LCSD with
regards to decreasing cardiac events in patients with LQTS and
CPVT [6,9,10]. As LCSD is not a curative treatment and does not
necessarily prevent sudden death, ICD implantation is recom-
mended for at risk patients and LCSD remains underutilized,
despite the proven beneﬁts of this procedure [4–6,9,10]. Indeed,
the most recently published guidelines for treating patients with
primary arrhythmia syndromes recommend LCSD as a Class IIb
treatment for patients with CPVT and as Classes I and IIa for
patients with LQTS [21]. Indeed; lifestyle modiﬁcations, ß-blocker
medication, LCSD, and ICD implantation can all be compared to a
cautious driver, anti-lock braking systems, seat belts, and air bags
in modern cars, where all of these options are complementary in
the prevention of trafﬁc accident-related injuries.Fig. 2. A resected specimen showing wavy peripheral nerve bundles in the left ﬁeld
and large polygonal ganglion cells in the right ﬁeld (hematoxylin–eosin stain,
40 ).2. Discussion
2.1. Surgical techniques for LCSD
Left stellectomy was the ﬁrst surgical technique developed for
LCSD and involves ablation of the entire left stellate ganglion.
However, this technique provides only limited cardiac protection
and causes Horner syndrome [10]. An improved technique is left
cervicothoracic sympathectomy, in which both the entire left
stellate ganglion and the ﬁrst four or ﬁve left thoracic ganglia are
removed. While this too is associated with Horner syndrome, it
does yield improved cardiac protection. The recently introduced
high thoracic left sympathectomy (HTLS) technique, in which the
lower half of the stellate ganglion and the ﬁrst four or ﬁve left
thoracic ganglia are removed, provides adequate cardiac protec-
tion and is associated with a very low incidence of Horner syn-
drome. Indeed, HTLS is the most commonly performed LCSD
procedure in the majority of treatment centers and resection of
the lower half of the left stellate ganglion is considered critical to
the antiﬁbrillatory effect of LCSD [6,10,22].
In conventional LCSD, the supraclavicular extrapleural
approach is most frequently used [9]. In this approach, a small
incision is made in the left subclavicular area, the anterior scalene
muscle and phrenic nerve are retracted, the pleural ligament is
cut, and the stellate ganglion and left sympathetic chain are iso-
lated and severed [23]. Experienced centers have reported the
duration of this procedure as 35–40 minutes [10]. However, con-
ventional LCSD carries the same risks as those associated with
open thoracotomy.
Video-assisted thoracoscopy has been used for upper thoracic
sympathectomy for hyperhidrosis since the early 1990s. This mini-
mally invasive technique has progressively evolved and been reﬁned
in recent years and the ﬁrst report of video-assisted thoracoscopic
surgery (VATS)-LCSD for patients with LQTS was published in 2003
[24]. In this procedure, patients are placed under general anesthesia
and positioned in the right lateral decubitus position. Two or threesmall incisions are made in the left chest along the mid-axillary
line; in order to accommodate a camera, a grasper, and an electro-
cautery hook dissector [15] (Figs. 1 and 2). Thoracoscopy is asso-
ciated with a lower risk proﬁle than open thoracotomy as well as
reduced complication rates, shorter hospital stays, and a lower
pleural drainage time [25]. Further advantages of VATS-LCSD when
compared with conventional LCSD include a more extensive and
accurate sympathetic chain resection due to the magniﬁed surgical
ﬁeld, as well as a lower risk of Horner syndrome as less traction is
applied to the stellate ganglion and sympathetic chain [12]. How-
ever, transient Horner syndrome may still develop as a result of
compression and swelling of the upper half of the stellate ganglion
[12,13]. When performed as described, the VATS-LCSD procedure is
usually completed within an hour. While no chest tube is typically
required, certain centers do routinely insert a small chest tube that
is subsequently removed 1 or 2 days post-procedure. Patients are
generally discharged 1 or 2 days after undergoing VATS-LCSD
[12,17].
2.2. Effectiveness of LCSD
LCSD has been used to treat LQTS patients for more than 40
years. Many studies have reported the efﬁcacy of LCSD and the
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conventional LCSD was published in 1991 [9]. After LCSD, the
number of symptomatic patients decreased signiﬁcantly (po
0.001) from 99% to 45% and the number of cardiac events per
patient decreased from 22 to 1. In 2004, the largest study inves-
tigating LCSD in LQTS patients (n¼147) thus far was published
[10]. The majority of patients were at high risk of cardiac events;
99% were symptomatic, with an extremely prolonged mean QTc
interval (543765 ms); and 75% suffered from recurrent syncope
after administration of maximum-dose β-blockers. After conven-
tional LCSD, 46% of patients were asymptomatic and the mean
annual number of cardiac events dropped by 91% [10]. In
5 patients who had undergone LCSD for multiple ICD shocks and
electrical storms, the number of shocks experienced decreased by
95% (p¼0.02) during the follow-up period. Interestingly, that
study suggested that the results of LCSD are dependent on the
experience and skill of the surgeon [10]. While a marked decrease
in the number of cardiac events after conventional or VATS-LCSD
is observed in the majority of studies, 20–50% of patients with
LQTS remain symptomatic [9,10,12,13,15–17]. Thus, LCSD should
not be viewed as a curative or alternative treatment to ICD
implantation in high-risk LQTS patients [9,10,13,16], but rather as
an event-attenuating procedure.
LCSD appears to be very effective in LQT1 and LQT3 patients,
although certain studies with inconclusively small sample sizes have
suggested it may be inadequate for the treatment of LQT8 patients
[10,13,14]. Studies investigating the efﬁcacy of LCSD for the treatment
of LQTS patients with ß-blocker intolerance have shown excellent
results with no cardiac events occurring during follow-up; however,
the majority of patients in one study did decrease or discontinue
their ß-blocker dosage [13]. This type of adjunctive LCSD treatment
in ß-blocker-intolerant patients on zero or low doses of these agents
appears promising. Prophylactic LCSD may also be considered for
selected asymptomatic or low-risk LQTS patients as an alternative to
life-long medication of uncertain signiﬁcance.
The ﬁrst study to investigate the effectiveness of LCSD in CPVT
patients was published in 2008 [11]. Thereafter, many small studies
with short follow-up periods and no deﬁnitive conclusions have been
published [12,14–17,26]. A recently published multicenter study that
included many of these smaller previous studies showed that LCSD
was associated with a remarkable reduction in both the percentage
of symptomatic patients (from 100% to 32% (po0.001)) as well as theFig. 3. Epinephrine test according to the Shimizu protocol [27] performed in a young wo
LCSD (upper strip) shows a markedly prolonged QT interval and premature ventricular co
5 days after LCSD (lower strip) using the same protocol shows prolonged QT intervals, b
daily ß-blocker treatment. LCSD: left cardiac sympathetic denervation.mean annual rate of events per patient, which dropped by 92% (from
3.4 to 0.5 per person per year (po0.001)) [6]. In that study, the
average number of post-LCSD ICD shocks also dropped signiﬁcantly
by 93% (from 3.6 to 0.6 per person per year (po0.001)) and the
number of patients experiencing electrical storms was markedly
reduced after LCSD (from 11 in 29 patients with ICDs (38%) to just 4
(14%)) [6]. These ﬁndings are of great signiﬁcance, as the pain and
fear associated with ICD shocks increases catecholamine release and
could initiate electrical storms [6]. LCSD in patients with CPVT and an
ICD could therefore prevent or decrease the ICD discharges asso-
ciated with shock-associated sympathetic surges [6,11].
2.3. Complications of LCSD
In a previous study on conventional LCSD, Horner syndrome
was observed in the majority of patients shortly after the proce-
dure and generally ceased at a later stage [9]. Numerous recently
published studies have reported no signiﬁcant complications in
VATS-LCSD; with the exception of a small number of cases of
refractory ventricular arrhythmias, spontaneously resolving
pneumothorax, and transient Horner syndrome [4,8,12–17,26]. In
addition, a few cases of harlequin facial ﬂushing and asymmetrical
facial sweating, which are clinically more benign, have been
reported [12,14,15,17].
There has been some concern with regards to controlling
bleeding in cases of hemorrhage from the stellate ganglion artery
during VATS-LCSD [22]. However, there have been no reported
cases of uncontrolled bleeding or conversion to a traditional open
thoracotomy during VATS-LCSD as yet.
2.4. Prediction of LCSD Efﬁcacy
Clinical characteristics and shortened QTc intervals after LCSD
are not useful for predicting the efﬁcacy of this procedure in
patients with LQTS. Average pre- and postoperative QTc values are
not signiﬁcantly different post-LCSD in patients with LQTS [9,10].
Normalization of QT intervals post-LCSD may occur in certain
patients with LQTS, while complete suppression of syncopal epi-
sodes may be observed despite the persistence of prolonged QT
intervals [9,12]. Therefore, the efﬁcacy of LCSD should be judged
only on the development of symptoms or cardiac events during
the follow-up period. One multicenter study suggested that amanwith long QT syndrome and aborted cardiac arrest. The epinephrine test before
ntraction, followed by torsades de pointes. A follow-up epinephrine test performed
ut no arrhythmia. The patient remained symptom free for more than 3 years with
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LQTS was a signiﬁcant predictor of efﬁcacy post-procedure [10].
The results showed that patients with continued QTcZ500 ms at
6 months post-LCSD remained at high risk for subsequent events;
while patients with only syncope and a post-LCSD QTco500 ms
were at a very low risk of adverse events. A further recent study
showed that patients with LQTS that experienced cardiac events
post-LCSD had signiﬁcantly longer baseline QTcs, were more likely
to have pre-procedural ICDs and, consequently, to have received
pre-procedural ICD shocks when compared to patients without
cardiac events post-LCSD [13]. The clinical role of the epinephrine
infusion test [27] post-LCSD remains uncertain (Fig. 3).
Among CPVT patients, predictors of LCSD efﬁcacy are unclear
with the exception of extent of denervation. Patients with
incomplete denervation, generally caused by sparing the lower
half of the left stellate ganglion, have been found to experience
signiﬁcantly more cardiac events post-LCSD when compared to
those with complete denervation [6].
Unfortunately, failure to treat or predict LCSD efﬁcacy may
result in sudden death in young patients. Uncertain clinical pre-
dictors and possible medicolegal conﬂicts could lead clinicians to
recommend ICD implantation over LCSD. Thus, there is an urgent
need for improved predictors before LCSD can be more widely-
used, especially in moderate- to high-risk patients.3. Conclusions
LCSD is highly effective in preventing cardiac events in patients
with LQTS and CPVT and presents an important therapeutic option
for these patients. Whenever syncope occurs despite optimal
medical therapy, LCSD should be considered as a next step in the
treatment plan.Conﬂicts of interest
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